Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-β-lactamase inhibitor combination

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 5036-5039

  Jones, Ronald N ^a   Holliday, Nicole M ^b   Krause, Kevin M ^c  

^a JMI LABORATORIES   (United States)

^b Thermo Fisher Scientific   (United States)

^c Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS LUGDUNENSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS INFECTIONS; VALIDATION STUDY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84940186561     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00021-15     Document Type: Article

References (16)

1. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
2. Flamm RK, Farrell DJ, Sader HS, Jones RN. 2014. Ceftazidimeavibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intraabdominal, and urinary tract infections in U.S. medical centers (2012). J Antmicrob Chemother 69:1589-1598. http://dx.doi.org/10.1093/jac/dku025.
3. 90 of European Gram-negative bacterial clinical isolates to the epidemiological cutoff value. J Chemother 26:333-338. http://dx.doi.org/10.1179/1973947813Y.0000000145.
4. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
5. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
6. Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaume C, Seys C, Stachyra T, Fairley M, Guitton M, Lampilas M. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J Antimicrob Chemother 54:410-417. http://dx.doi.org/10.1093/jac/dkh358.
7. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68:1183-1192. http://dx.doi.org/10.1093/jac/dks523.
8. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. 2012. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28:1921-1931. http://dx.doi.org/10.1185/03007995.2012.748653.
9. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D for the Infectious Diseases Society of America. 2013. 10 x ′20 progress: development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
10. th ed. CLSI M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
11. th Gen Meet Am Soc Microbiol, Boston, MA. American Society for Microbiology, Washington, DC.
12. Fritsche TR, Moet GJ, Jones RN. 2004. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase. Clin Microbiol Infect 10:857-860. http://dx.doi.org/10.1111/j.1198-743X.2004.00946.x.
13. Jones RN, Streit JM, Fritsche TR. 2004. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 23:197-199. http://dx.doi.org/10.1016/j.ijantimicag.2003.07.008.
14. Jones RN, Holliday NM, Rhomberg PR. 2015. Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone. J Clin Microbiol 53:657-659. http://dx.doi.org/10.1128/JCM.02769-14.
15. th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Covis Pharmaceuticals. 2014. Fortaz prescribing information. Covis Pharmaceuticals, Cary, NC. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/050578s055,050634s023lbledt.pdf.